PMID- 27590538
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20171207
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 72
IP  - 4
DP  - 2017 Apr
TI  - Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific 
      immunotherapy in mice.
PG  - 570-578
LID - 10.1111/all.13041 [doi]
AB  - BACKGROUND: Immunomodulatory interventions play a key role in the treatment of 
      infections and cancer as well as allergic diseases. Adjuvants such as micro- and 
      nanoparticles are often added to immunomodulatory therapies to enhance the 
      triggered immune response. Here, we report the immunological assessment of novel 
      and economically manufactured microparticle adjuvants, namely strontium-doped 
      hydroxyapatite porous spheres (SHAS), which we suggest for the use as adjuvant 
      and carrier in allergen-specific immunotherapy (ASIT). METHODS AND RESULTS: 
      Scanning electron microscopy revealed that the synthesis procedure developed for 
      the production of SHAS results in a highly homogeneous population of spheres. 
      Strontium-doped hydroxyapatite porous spheres bound and released proteins such as 
      ovalbumin (OVA) or the major cat allergen Fel d 1. SHAS-OVA were taken up by 
      human monocyte-derived dendritic cells (mdDCs) and murine DCs and did not have 
      any necrotic or apoptotic effects even at high densities. In a murine model of 
      ASIT for allergic asthmatic inflammation, we found that OVA released from 
      subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4(+) 
      and CD8(+) T cells. Allergen-specific immunotherapy with SHAS-OVA as compared to 
      soluble OVA resulted in similar humoral responses but in a higher efficacy as 
      assessed by symptom scoring. CONCLUSION: We conclude that SHAS may constitute a 
      suitable carrier and adjuvant for ASIT with great potential due to its unique 
      protein-binding properties.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Garbani, M
AU  - Garbani M
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos Platz, Switzerland.
FAU - Xia, W
AU  - Xia W
AD  - Applied Materials Science, Department of Engineering Sciences, Angstrom 
      Laboratory, Uppsala University, Uppsala, Sweden.
FAU - Rhyner, C
AU  - Rhyner C
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos Platz, Switzerland.
FAU - Prati, M
AU  - Prati M
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos Platz, Switzerland.
FAU - Scheynius, A
AU  - Scheynius A
AD  - Department of Clinical Science and Education, Karolinska Institutet, and Sachs' 
      Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.
FAU - Malissen, B
AU  - Malissen B
AD  - Centre d'Immunologie de Marseille-Luminy (CIML), INSERM U1104, CNRS UMR7280, UM2 
      Aix-Marseille Universite, Marseille Cedex 9, France.
FAU - Engqvist, H
AU  - Engqvist H
AD  - Applied Materials Science, Department of Engineering Sciences, Angstrom 
      Laboratory, Uppsala University, Uppsala, Sweden.
FAU - Maurer, M
AU  - Maurer M
AD  - Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite 
      -Universitatsmedizin Berlin, Berlin, Germany.
FAU - Crameri, R
AU  - Crameri R
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos Platz, Switzerland.
FAU - Terhorst, D
AU  - Terhorst D
AD  - Centre d'Immunologie de Marseille-Luminy (CIML), INSERM U1104, CNRS UMR7280, UM2 
      Aix-Marseille Universite, Marseille Cedex 9, France.
AD  - Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite 
      -Universitatsmedizin Berlin, Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20161222
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Allergens)
RN  - 0 (Hydroxyapatites)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Phosphatidylethanolamines)
RN  - 0 (strontium hydroxyapatite)
RN  - 2462-63-7 (dioleoyl phosphatidylethanolamine)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - YZS2RPE8LE (Strontium)
SB  - IM
MH  - *Adjuvants, Immunologic
MH  - Allergens/administration & dosage/*immunology
MH  - Animals
MH  - Dendritic Cells/immunology/metabolism
MH  - *Desensitization, Immunologic/methods
MH  - Disease Models, Animal
MH  - Female
MH  - *Hydroxyapatites/chemistry
MH  - Hypersensitivity/*immunology/therapy
MH  - Immunization
MH  - Immunoglobulin E/immunology
MH  - Immunoglobulin G/immunology
MH  - Lymphocyte Activation/immunology
MH  - Mice
MH  - Ovalbumin/immunology
MH  - *Phosphatidylethanolamines/chemistry
MH  - *Strontium/chemistry
MH  - T-Lymphocyte Subsets/immunology/metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - allergy model
OT  - dendritic cells
OT  - immunotherapy
OT  - microparticles
EDAT- 2016/09/04 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/09/04 06:00
PHST- 2016/09/01 00:00 [accepted]
PHST- 2016/09/04 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/09/04 06:00 [entrez]
AID - 10.1111/all.13041 [doi]
PST - ppublish
SO  - Allergy. 2017 Apr;72(4):570-578. doi: 10.1111/all.13041. Epub 2016 Dec 22.